T cell proliferation and the calculation of a stimulation index are one of the mostly widely used methods in both mouse and man to demonstrate antigen specific immunity. We propose to define a """"""""second generation"""""""" assay to replace traditional lymphocyte proliferation assays using [3H]thymidine uptake. Multiparameter flow cytometry will be used to assess antigen-specific T cell proliferation by measuring incorporation of BrdU, a thymidine analog. In addition to proliferating T cells, surface markers associated with proliferating cells will be examined. Surface markers to be examined will include CO27, CD45RO/RA, and CO95. These are all markers that can be used, singly or in combination, to distinguish naive from memory cells. Antigen-specific BrdU incorporation will be used to identify proliferating antigen-responsive cells, so that analysis of other markers can be perfoffi1ed by gating on these cells. In a preliminary study using SEB as a stimulus, positive correlation was observed between flow cytometric measurement of proliferating CD4+ T cells by BrdU incorporation and a standard proliferation assay measuring [3H]thymidine uptake by PBMC. We propose to extend the use of BrdU proliferation assay using flow cytometry in assessing T cell proliferative responses to CMV, flu, and tumor antigens.
The aim of this pilot project will be to correlate lymphocyte proliferation assay using non-radioactive BrdU incorporation measured by multiparametric flow cytometry and a standard radioactive [3H]thymidine incorporation assay in the following systems: CMV, influenza, and at least one of the candidate cancer antigens to be evaluated by the consortium (MAGE-3, HER2, CEA, or gp100).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Slota, Meredith; Lim, Jong-Baeck; Dang, Yushe et al. (2011) ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 10:299-306
Coveler, Andrew L; Goodell, Vivian; Webster, Devon J et al. (2009) Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat 113:95-100
Maecker, Holden T (2009) Multiparameter flow cytometry monitoring of T cell responses. Methods Mol Biol 485:375-91
Ladd, Jon; Lu, Hailing; Taylor, Allen D et al. (2009) Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 70:1-6
Maecker, Holden T; Hassler, Jeffrey; Payne, Janice K et al. (2008) Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 9:9
Goodell, Vivian; Waisman, James; Salazar, Lupe G et al. (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449-54
Park, Kyong Hwa; Gad, Ekram; Goodell, Vivian et al. (2008) Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68:8400-9
Goodell, Vivian; McNeel, Douglas; Disis, Mary L (2008) His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 9:23
Siebert, Janet C; Inokuma, Margaret; Waid, Dan M et al. (2008) An analytical workflow for investigating cytokine profiles. Cytometry A 73:289-98
Goodell, Vivian; dela Rosa, Corazon; Slota, Meredith et al. (2007) Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol 8:21

Showing the most recent 10 out of 23 publications